PHIO - Latest News
Phio Pharmaceuticals Corp. (PHIO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $10.3M. Beta to the broader market is 0.81.
The article list below shows the most recent PHIO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PHIO Headlines
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
newsfilecorp.com - Jul 15, 2026
Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds King of Prussia, Pennsylvania--(Newsfile Corp. -
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
newsfilecorp.com - Jun 26, 2026
Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Co
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
feeds.newsfilecorp.com - Jun 25, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
newsfilecorp.com - Jun 24, 2026
Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manufactured supply will support upcoming clinical tri
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
feeds.newsfilecorp.com - Jun 18, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp.
How News Affects PHIO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PHIO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PHIO news questions
- What is the latest PHIO news headline?
- The most recent PHIO headline (Jul 15, 2026) is "Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PHIO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PHIO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PHIO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.